Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

The effects of marijuana smoking on lung function in older people

Wan C. Tan, Jean Bourbeau, Shawn D. Aaron, James C. Hogg, François Maltais, Paul Hernandez, Darcy D. Marciniuk, Kenneth R. Chapman, Teresa To, J. Mark FitzGerald, Brandie L. Walker, Jeremy Road, Liyun Zheng, Guohai Zhou, Trevor Yau, Andrea Benedetti, Denis O'Donnell, Don D. Sin on behalf of the CanCOLD Collaborative Research Group
European Respiratory Journal 2019; DOI: 10.1183/13993003.00826-2019
Wan C. Tan
1The University of British Columbia, Center for Heart Lung Innovation, St Pauls's Hospital, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: wan.tan@hli.ubc.ca
Jean Bourbeau
2Research Institutte McGill University Health Center, McGill University, Montreal, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jean Bourbeau
Shawn D. Aaron
3The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James C. Hogg
1The University of British Columbia, Center for Heart Lung Innovation, St Pauls's Hospital, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Maltais
4Institut Universitaire de cardiologie et de pneumologie de Québec, Université Laval, Quebec City, Quebec, Canada)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Hernandez
5Department of Medicine, Dalhousie University, Halifax, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darcy D. Marciniuk
6Respiratory Research Centre, University of Saskatchewan, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth R. Chapman
7University of Toronto, Toronto, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kenneth R. Chapman
Teresa To
8Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Mark FitzGerald
9University of British Columbia, Department of Medicine, Vancouver General Hospital, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brandie L. Walker
10University of Calgary(BLW), Alberta, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy Road
9University of British Columbia, Department of Medicine, Vancouver General Hospital, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liyun Zheng
1The University of British Columbia, Center for Heart Lung Innovation, St Pauls's Hospital, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guohai Zhou
1The University of British Columbia, Center for Heart Lung Innovation, St Pauls's Hospital, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trevor Yau
1The University of British Columbia, Center for Heart Lung Innovation, St Pauls's Hospital, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Benedetti
2Research Institutte McGill University Health Center, McGill University, Montreal, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denis O'Donnell
11Queen's University, Kingston, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Denis O'Donnell
Don D. Sin
1The University of British Columbia, Center for Heart Lung Innovation, St Pauls's Hospital, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background Previous studies have associated marijuana exposure with increased respiratory symptoms and chronic bronchitis among long-term cannabis smokers.The long-term effects of smoked marijuana on lung function remain unclear.

Methods We determined the association of marijuana smoking with the risk of spirometrically-defined COPD [post-bronchodilator FEV1/FVC<0·7] in 5291 population-based individuals and the rate of decline in FEV1 in a subset of 1285 men and women, aged 40 years and older, who self-reported use (or nonuse) of marijuana and tobacco cigarettes and performed spirometry before and after inhaled bronchodilator on multiple occasions. Analysis for the decline in FEV1 was performed using random mixed effects regression models adjusted for age, gender, and body mass index. Heavy tobacco smoking and marijunana smoking was defined as >20 pack-years and >20 joint-years, respectively.

Results Approximately 20% of participants had been or were current marijuana smokers with most also having smoked tobacco cigarettes (83%). Among heavy marijuana users, the risk of COPD was significantly increased (adjusted odds ratio, aOR, 2.45; 95% CI, 1.55–3.88). Compared to never-smokers of marijuana and tobacco, heavy marijuana smokers and heavy tobacco smokers experienced a faster decline in FEV1 by 29·5 mL·year−1 (p=0·0007) and 21·1 mL·year−1 (p<0.0001), respectively.Those who smoked both experienced a decline of 32.31 mL·year−1 (p<.0001).

Interpretation Heavry marijuana smoking increases the risk of COPD and accelerates FEV1 decline in concomitant tobacco smokers beyond that observed with tobacco alone.

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Tan reports grants from Canadian Institute of Heath Research (CIHR/Rx&D Collaborative Research Program Operating Grants- 93326) with industry partners Astra Zeneca Canada Ltd., Boehringer-Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd, Merck, Novartis Pharma Canada Inc., Nycomed Canada Inc., Pfizer Canada Ltd., during the conduct of the study.

Conflict of interest: Dr. Bourbeau reports grants from Canadian Institute of Heath Research (CIHR/Rx&D Collaborative Research Program Operating Grants- 93326) with industry partners Astra Zeneca Canada Ltd., Boehringer-Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd, Merck, Novartis Pharma Canada Inc., Nycomed Canada Inc., Pfizer Canada Ltd., during the conduct of the study.

Conflict of interest: Dr. Aaron has nothing to disclose.

Conflict of interest: Dr. Hogg has nothing to disclose.

Conflict of interest: Dr. Maltais has nothing to disclose.

Conflict of interest: Dr. Hernandez reports grants from Canadian Institute Health Research, during the conduct of the study; grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, grants and personal fees from GlaxoSmithKline, personal fees from Merck, grants and personal fees from Novartis, grants and personal fees from Takeda, personal fees from Grifols, grants from CSL Behring, personal fees from Pfizer, personal fees from Almirall, outside the submitted work.

Conflict of interest: Dr. Marciniuk has nothing to disclose.

Conflict of interest: Dr. Chapman reports grants from Novartis, grants from Almirall, grants from Boehringer Ingelheim, grants from Forest, grants from GSK, grants from AstraZeneca, grants from Amgen, grants from Roche, grants from CSL Behring, grants from Grifols, grants from Genentech, grants from Kamada, during the conduct of the study; other from CIHR-GSK Research Chair in Respiratory Health Care Delivery, outside the submitted work.

Conflict of interest: Dr. To has nothing to disclose.

Conflict of interest: Dr. FitzGerald has nothing to disclose.

Conflict of interest: Dr. Walker reports grants from Canadian Institute of Health Research, grants from AstraZeneca Canada Ltd, grants from Boehringer Ingelheim Canada, grants from GlaxoSmithKline Canada, grants from Novartis, during the conduct of the study; grants from Respiratory Health Strategic Clinical Network Alberta, personal fees from AtraZeneca, personal fees from GlaxoSmithKline, personal fees from Novartis, outside the submitted work.

Conflict of interest: Dr. Road has nothing to disclose.

Conflict of interest: Dr. Zheng has nothing to disclose.

Conflict of interest: Dr. Zhou has nothing to disclose.

Conflict of interest: Dr. Yau has nothing to disclose.

Conflict of interest: Dr. Benedetti has nothing to disclose.

Conflict of interest: Dr. O'donnell has nothing to disclose.

Conflict of interest: Dr. Sin reports grants from AstraZeneca, during the conduct of the study; grants from Merck, personal fees from Sanofi-Aventis, personal fees from Regeneron, grants and personal fees from Boehringer Ingelheim, grants and personal fees from AstraZeneca, personal fees from Novartis, outside the submitted work.

  • Copyright ©ERS 2019
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 57 Issue 1 Table of Contents
European Respiratory Journal: 57 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The effects of marijuana smoking on lung function in older people
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
The effects of marijuana smoking on lung function in older people
Wan C. Tan, Jean Bourbeau, Shawn D. Aaron, James C. Hogg, François Maltais, Paul Hernandez, Darcy D. Marciniuk, Kenneth R. Chapman, Teresa To, J. Mark FitzGerald, Brandie L. Walker, Jeremy Road, Liyun Zheng, Guohai Zhou, Trevor Yau, Andrea Benedetti, Denis O'Donnell, Don D. Sin
European Respiratory Journal Jan 2019, 1900826; DOI: 10.1183/13993003.00826-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The effects of marijuana smoking on lung function in older people
Wan C. Tan, Jean Bourbeau, Shawn D. Aaron, James C. Hogg, François Maltais, Paul Hernandez, Darcy D. Marciniuk, Kenneth R. Chapman, Teresa To, J. Mark FitzGerald, Brandie L. Walker, Jeremy Road, Liyun Zheng, Guohai Zhou, Trevor Yau, Andrea Benedetti, Denis O'Donnell, Don D. Sin
European Respiratory Journal Jan 2019, 1900826; DOI: 10.1183/13993003.00826-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: A randomised clinical trial
  • Lung transplantation for sarcoidosis: outcome and prognostic factors
  • Chronic Pulmonary Aspergillosis: Prevalence, favouring pulmonary diseases and prognosis
Show more Original article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society